The laboratory focuses on three main themes:
- Developing innovative pharmacological protocols for immunosuppression and cellular therapies to induce immunological tolerance to kidney transplantation in humans
- Discovering new drugs that can slow or stop the progression of autosomal dominant polycystic kidney disease (ADPKD) to end-stage renal failure
- Developing screening and intervention strategies to prevent the onset of chronic kidney diseases and their complications, particularly in emerging countries.
Inducing immunological tolerance to organ transplantation with mesenchymal stromal cells
The aim is to evaluate the tolerability and safety of systemic infusion of autologous or allogeneic mesenchymal stromal (MSC) cells peri-transplant in kidney or liver transplantation. In parallel, the ability of these cells to modulate the recipient's immune system is studied in order to induce immunological tolerance towards the transplanted organ.
Identifying new drugs for polycystic kidney disease
Our research aims to establish the efficacy and safety of innovative pharmacological therapies for ADPKD and its extra-renal manifestations in clinical trials. We focus specifically on slow-release somatostatin analogues, such as octreotide-LAR, and their use in patients with normal renal function or with different degrees of renal insufficiency. We also work to identify functional markers and radiological images that can predict the efficacy of the proposed therapies.
Epidemiology of kidney diseases in the Global Burden of Diseases (GBD) study
In collaboration with the Institute of Health Metrics and Evaluation in Seattle (USA), which coordinates the GBD project, we help to estimate the number of patients globally with chronic kidney diseases, as well as the number of deaths that are attributable to these diseases, and their risk factors.
International Consensus on Cardiopulmonary Resuscitation.